Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 10 (2), 193-203

Acetyl L-carnitine Slows Decline in Younger Patients With Alzheimer's Disease: A Reanalysis of a Double-Blind, Placebo-Controlled Study Using the Trilinear Approach

Affiliations
Clinical Trial

Acetyl L-carnitine Slows Decline in Younger Patients With Alzheimer's Disease: A Reanalysis of a Double-Blind, Placebo-Controlled Study Using the Trilinear Approach

J O Brooks 3rd et al. Int Psychogeriatr.

Abstract

Objectives: To assess the longitudinal effects of acety-L-carnitine (ALC) on patients diagnosed with Alzheimer's disease.

Design: Longitudinal, double-blind, parallel-group, placebo-controlled.

Setting: Twenty-four outpatient sites across the United States.

Participants: A total of 334 subjects diagnosed with probable Alzheimer's disease by NINCDS-ADRDA criteria. These data were originally reported by Thal and colleagues (1996).

Measurements: Cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS) given every 3 months for 1 year.

Results: The average rate of change was estimated using the trilinear approach, which allows for periods of both change and stability. Both the ALC group and the placebo group exhibited the same mean rate of change on the ADAS (0.68 points/month). However, a multiple regression analysis revealed a statistically significant Age x Drug interaction characterized by younger subjects benefiting more from ALC, significant, cutpoint for ALC benefit was 61 years of age.

Conclusions: ALC slows the progression of Alzheimer's disease in younger subjects, and the use of the trilinear approach to estimate the average rate of change may prove valuable in pharmacological trials.

Similar articles

  • Acetyl-L-carnitine for Dementia
    S Hudson et al. Cochrane Database Syst Rev (2), CD003158. PMID 12804452. - Review
    There is evidence for benefit of ALC on clinical global impression, but there was no evidence using objective assessments in any other area of outcome. Given the large nu …
  • Galantamine for Alzheimer's Disease
    J Olin et al. Cochrane Database Syst Rev (3), CD001747. PMID 12137632. - Review
    Patients in these trials were similar to those seen in earlier anti dementia AD trials, and consisted predominantly of mildly to moderately impaired outpatients. Galantam …
  • Galantamine for Alzheimer's Disease
    J Olin et al. Cochrane Database Syst Rev (4), CD001747. PMID 11687119. - Review
    Patients in these trials were similar to those seen in earlier antidementia AD trials, and consisted primarily of mildly to moderately impaired outpatients. Galantamine's …
  • Nilvadipine in Mild to Moderate Alzheimer Disease: A Randomised Controlled Trial
    B Lawlor et al. PLoS Med 15 (9), e1002660. PMID 30248105. - Clinical Trial
    The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease.
  • Donepezil for Vascular Cognitive Impairment
    R Malouf et al. Cochrane Database Syst Rev (1), CD004395. PMID 14974068. - Review
    Evidence from the available studies support the benefit of donepezil in improving cognition function, clinical global impression and activities of daily living in patient …
See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback